FDA-Cleared AI Platform SOMNUM Reduces Sleep Clinical Trial Timelines by 50%
核心洞察
HoneyNaps (搜索)' FDA-cleared AI software SOMNUM (搜索) automates polysomnography data analysis, reducing manual scoring time from 3-4 hours to minutes per case.
The platform has enabled pharmaceutical and medical device companies to accelerate clinical trial pipelines by 50% while increasing data-processing speed by over 70%.
SOMNUM (搜索) incorporates explainable AI technology to ensure transparency and meets stringent regulatory quality standards for sleep-related clinical trials.
HoneyNaps (搜索) announced that its FDA-cleared AI-based sleep disorder diagnostic support software, SOMNUM (搜索)™, is significantly reducing clinical trial timelines and costs for pharmaceutical and medical device companies through enhanced polysomnography data analysis efficiency.
Revolutionary AI-Powered Sleep Analysis
SOMNUM (搜索)™ represents a medical AI software solution designed to automatically analyze polysomnography (PSG) data, identifying sleep stages and key events including apnea, hypopnea, and arousals using advanced artificial intelligence-based PSG scoring. Following its FDA 510(k) clearance last year, SOMNUM™ has been formally recognized as a validated analytical tool for sleep-related clinical trials and medical device evaluations.
The traditional PSG scoring process required specialists to manually review and classify data for more than three to four hours per case, resulting in high labor and time costs. SOMNUM (搜索)™ automates this process, shortening scoring time to just minutes, while clinicians review and verify the results to maintain diagnostic quality.
Significant Clinical Trial Efficiency Gains
By integrating SOMNUM (搜索)™, pharmaceutical companies and medical device manufacturers have achieved substantial operational improvements. The platform has enabled companies to increase data-processing speed by more than 70% and reduce overall study timelines by approximately 50%. Additionally, scoring labor costs and quality-control expenses have dropped by 80-90%.
"SOMNUM (搜索)'s PSG AI scoring technology is fundamentally transforming the traditionally time-consuming manual scoring process that has long been a bottleneck in sleep-related clinical trials," stated Taekyoung (Sean) Ha, PhD, President of HoneyNaps (搜索) USA. "Backed by FDA clearance, SOMNUM™ is now delivering tangible improvements in research efficiency and cost reduction for global pharmaceutical and medical device companies."
Advanced Technology Features
SOMNUM (搜索)™ incorporates explainable AI (XAI) technology, enabling clinicians to review the rationale behind the AI's scoring decisions. This ensures transparency and verifiability of trial data, meeting the stringent quality standards required by global regulatory agencies.
The company offers an AI-based re-scoring service for already-scored PSG datasets, providing an objective check on the accuracy of existing scoring results. CROs leverage this re-scoring solution to secure data quality while shortening trial timelines and strengthening the reliability of data submitted to regulatory bodies.
Global Market Expansion
HoneyNaps (搜索) is expanding its global clinical-market presence with SOMNUM (搜索)™ at the core of its business strategy. The company is currently in discussions with U.S. pharmaceutical firms regarding the application of SOMNUM™ in sleep-related clinical studies and has established strategic partnerships with multiple contract research organizations (CROs).
Through these collaborations, HoneyNaps (搜索) provides a large-scale biosignal-analysis platform essential for sleep-medicine and neurological clinical trials, delivering both accelerated pipelines and enhanced data accuracy. The company is currently collaborating with major tertiary hospitals and sleep centers in Korea, as well as university hospitals and clinical institutions across the United States and Europe.
Broad Clinical Applications
The technology is being used not only in clinical trials for sleep and wake-promoting therapeutics, but also in evaluating the effectiveness of CPAP devices, sleep sensors, wearable devices, and a range of sleep-technology products. This versatility positions SOMNUM (搜索)™ as a comprehensive solution for various aspects of sleep medicine research and development.